Chongqing Pharscin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002907.SZ

Chongqing Pharscin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2023: 4.73%

Chongqing Pharscin Pharmaceutical Co., Ltd. Net Income Margin is 4.73% for the year ending December 31, 2023, a -62.27% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2022 was 12.53%, a 15.54% change year over year.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2021 was 10.85%, a -19.69% change year over year.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2020 was 13.51%, a -33.00% change year over year.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2019 was 20.16%, a 3.22% change year over year.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
SV Wall Street
Shenzhen Stock Exchange: 002907.SZ

Chongqing Pharscin Pharmaceutical Co., Ltd.

CEO Ms. Xiaoying Liu
IPO Date Oct. 20, 2017
Location China
Headquarters No. 89, Middle Sec of Huangshan Ave
Employees 1,411
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies
Description

Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. Chongqing Pharscin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Chongqing, China.

StockViz Staff

February 3, 2025

Any question? Send us an email